Natera, Inc. $NTRA Stock: Robeco Institutional Asset Management B.V. Trims Position

Robeco Institutional Asset Management B.V. reduced its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 45.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 223,309 shares of the medical research company’s stock after selling 185,307 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Natera were worth $92,296,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Diversify Advisory Services LLC purchased a new stake in Natera in the third quarter worth $423,000. Focused Alpha LLC lifted its position in shares of Natera by 20.6% during the third quarter. Focused Alpha LLC now owns 2,096 shares of the medical research company’s stock worth $866,000 after purchasing an additional 358 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of Natera by 10.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 14,324 shares of the medical research company’s stock valued at $5,920,000 after purchasing an additional 1,317 shares during the period. Abel Hall LLC purchased a new stake in shares of Natera during the third quarter valued at $259,000. Finally, Kaufman Rossin Wealth LLC boosted its stake in shares of Natera by 21.1% during the third quarter. Kaufman Rossin Wealth LLC now owns 1,046 shares of the medical research company’s stock valued at $432,000 after purchasing an additional 182 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In related news, CEO Steven Chapman sold 1,273 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $413.31, for a total value of $526,143.63. Following the completion of the sale, the chief executive officer directly owned 96,926 shares of the company’s stock, valued at $40,060,485.06. This represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Fesko sold 6,517 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the transaction, the insider owned 197,257 shares in the company, valued at approximately $63,424,043.21. The trade was a 3.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 52,985 shares of company stock valued at $16,119,137. Insiders own 5.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on NTRA shares. Wells Fargo & Company upped their price target on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Piper Sandler lifted their price objective on shares of Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Robert W. Baird set a $348.00 price objective on shares of Natera in a research report on Friday, August 7th. UBS Group upped their target price on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of Natera from $360.00 to $460.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $374.64.

Natera Trading Up 1.8%

Shares of NTRA stock opened at $413.38 on Thursday. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41. The stock has a market capitalization of $59.59 billion, a price-to-earnings ratio of -303.95 and a beta of 1.50. The stock has a fifty day simple moving average of $363.64 and a two-hundred day simple moving average of $280.16.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business’s revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.74) EPS. Research analysts predict that Natera, Inc. will post -1.05 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.